Evolus Achieves Second Consecutive Quarter of Positive Adjusted EBITDA and Terminates $50M ATM Program
EOLS sits 46% above its 52-week low of $3.86 on elevated volume (2.0× avg).
Summary
Evolus reported positive Adjusted EBITDA for Q1 2026, terminated a $50 million ATM program without selling shares, and reaffirmed its full-year guidance, signaling improved financial health and reduced dilution risk.
Key Events · Earnings and Guidance · EOLS
-
Achieves Positive Adjusted EBITDA
Evolus reported $0.6 million in Adjusted EBITDA for the first quarter of 2026, marking the second consecutive quarter of profitability and a significant improvement from a $5.5 million loss in the prior year period.
-
Terminates $50 Million ATM Program
The company terminated its 'at-the-market' sales agreement, which had authorized the sale of up to $50.0 million in common stock. No shares were sold under this program prior to termination, removing a potential dilutive overhang.
-
Reaffirms Full-Year 2026 Outlook
Evolus reiterated its full-year 2026 net revenue guidance of $327 million to $337 million and continues to expect to achieve a low- to mid-single digit Adjusted EBITDA margin.
-
Discloses Potential Tariff Impact
The company noted a potential 15% U.S. tariff on patented pharmaceuticals from South Korea, which could affect its Jeuveau® product starting September 29, 2026, but stated it has flexibility to mitigate near-to-medium term impacts.
Analysis · EOLS · Life Sciences
Evolus's Q1 2026 results demonstrate a significant operational turnaround, achieving positive Adjusted EBITDA for the second consecutive quarter, which is a key milestone for the company's financial health. The termination of the $50 million 'at-the-market' program, under which no shares were sold, removes a substantial potential dilutive overhang (approximately 13.7% of current market cap), signaling improved capital position or reduced need for immediate external financing. While a new potential tariff on Jeuveau® from South Korea presents a future risk, the company's stated mitigation strategies temper immediate concerns. The reaffirmation of full-year guidance further reinforces management's confidence in continued growth and profitability.
At the time of this filing, EOLS was trading at $5.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $363M. The 52-week trading range was $3.86 to $12.28. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.